A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia-Reference-Cited by-同舟云学术

A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia

Published:2019-08-01 Issue:8 Volume:29 Page:1158-1167
ISSN:1050-7256
Container-title:Thyroid
language:en
Short-container-title:Thyroid

Author:

Zhou Jin¹,Waskowicz Lauren R.²,Lim Andrea¹,Liao Xiao-Hui³,Lian Brian⁴,Masamune Hiroko⁴,Refetoff Samuel³⁵,Tran Brian⁴,Koeberl Dwight D.²⁶,Yen Paul M.¹⁷⁸

Affiliation:

1. Cardiovascular and Metabolic Disorders Program, Duke-NUS Medical School, Singapore, Singapore.

2. Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina.

3. Department of Medicine, The University of Chicago, Chicago, Illinois.

4. Viking Therapeutics, San Diego, California.

5. Department of Pediatrics and Committee on Genetics, The University of Chicago, Chicago, Illinois.

6. Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina.

7. Department of Medicine, and Duke University Medical Center, Durham, North Carolina.

8. Department of Duke Molecular Physiology Institute, Duke University Medical Center, Durham, North Carolina.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2019.0007

Reference45 articles.

1. Recent development and gene therapy for glycogen storage disease type Ia

2. Glycogen storage disease type I and G6Pase-β deficiency: etiology and therapy

3. Glucose-6-phosphatase deficiency

4. Increased de novo Lipogenesis and Delayed Conversion of Large VLDL into Intermediate Density Lipoprotein Particles Contribute to Hyperlipidemia in Glycogen Storage Disease Type 1a

5. Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug discovery targeting thyroid hormone receptor β (THRβ) for the treatment of liver diseases and other medical indications;Acta Pharmaceutica Sinica B;2024-08

2. Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease;Journal of Clinical and Translational Hepatology;2024-07-31

3. Co-targeting ASK1 and THRβ synergistically improves steatohepatitis and fibrosis in a MASH animal model;Biochemical and Biophysical Research Communications;2024-04

4. Endocrine involvement in hepatic glycogen storage diseases: pathophysiology and implications for care;Reviews in Endocrine and Metabolic Disorders;2024-04-01

5. Cross-Talk Between Thyroid Disorders and Nonalcoholic Fatty Liver Disease: From Pathophysiology to Therapeutics;Hormone and Metabolic Research;2024-02-26